Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52702
Conference/Presentation Title: TCT-830 Feasibility and utility of anatomic and physiological evaluation of coronary disease with cardiac ct in severe aortic stenosis (FUTURE-AS registry).
Authors: Ihdayhid A.R.;Polsani V.;Fairbairn T.;Fitzgibbons T.;Ko B. ;Liu S.;Khoo J.;Coughlan F.;Shetty S.;Chatfield A.;Akodad M.;Raju V.;Kakouros N.;Lewin S.;Sathananthan J.;Webb J.;Wood D.;Leipsic J.;Sellers S.
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Ihdayhid) Curtin University, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia, Australia
(Polsani, Liu) Piedmont Heart Institute, Atlanta, Georgia, USA, United States
(Fairbairn) Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
(Fitzgibbons) UMass Memorial Health, Worcester, Massachusetts, USA, United States
(Ko) Victorian Heart Hospital, Melbourne, Victoria, Australia, Australia
(Khoo, Coughlan) University of British Columbia, Vancouver, British Columbia, Canada, Canada
(Shetty, Lewin) Fiona Stanley Hospital, Perth, Western Australia, Australia, Australia
(Chatfield) Wellington Hospital, Wellington, New Zealand, New Zealand
(Akodad) Institut Cardiovasculaire Paris Sud, Massy, France, France
(Raju) Fiona Stanley Hospital, Perth, Australia, Australia
(Kakouros) Umass Memorial Medical Center, Worcester, Alabama, USA, United States
(Sathananthan, Webb, Leipsic, Sellers) St Paul's Hospital, Vancouver, British Columbia, Canada, Canada
(Wood) UBC Centre for Cardiovascular Innovation, Vancouver, British Columbia, Canada, Canada
Presentation/Conference Date: 23-Oct-2024
Copyright year: 2024
Publisher: Elsevier Inc.
Publication information: Journal of the American College of Cardiology. Conference: Thirty-Sixth Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT). Walter E. Washington Convention Center, Washington United States. 84(18 Supplement) (pp B341), 2024. Date of Publication: 29 Oct 2024.
Journal: Journal of the American College of Cardiology
Abstract: Background: Coronary artery disease (CAD) is common in patients with severe aortic stenosis (AS) and may impact transcatheter aortic valve replacement (TAVR) procedural and long-term outcomes. Computed tomography coronary angiography (CTCA) and CT-derived fractional flow reserve (FFRCT) are tools used to assess CAD. However, adoption in the TAVR population is hindered by safety concerns with nitroglycerin and beta-blockers. The safety, accuracy, and utility of CTCA and FFRCT optimized with these medications for TAVR have not been established. Method(s): This international, multicenter, prospective registry included severe AS patients referred for TAVR, assessed for CAD with CTCA and FFRCT. Patients all received nitroglycerin and beta-blockers as needed to optimize image quality. Severe ventricular dysfunction, recent syncope/heart failure, critical hemodynamics, or prior revascularization were excluded. Significant CAD was defined as CTCA stenosis >=50% and FFRCT <=0.75. Primary endpoint was per-patient sensitivity and negative predictive value (NPV) of CTCA compared with invasive coronary angiography (ICA). Secondary endpoints included specificity and positive predictive value (PPV) of CTCA and FFRCT, safety, feasibility (non evaluable rate), and the utility of CTCA+FFRCT to reduce pre-TAVR ICA. Result(s): 327 patients (76 +/- 10 years, 53% men) underwent CTCA. CTCA was safe and well tolerated in nearly all patients, with self-limiting hypotension in 4 (1.2%). CTCA was evaluable in 326 patients (99.7%), with 9 (2.8%) having a non evaluable vessel. FFRCT was performed in 110 (33.6%) and ICA in 133 (40.7%). Per-patient sensitivity, specificity, NPV, and PPV of CTCA were 100%, 71.4%, 100%, and 75.9% and per-vessel 82.7%, 78.9%, 92.3%, and 59.9%. FFRCT improved specificity and PPV to 88.9% and 88.0% for per-patient and 95.1% and 81.8% for per-vessel analysis. Using observed reclassification rates from CTCA and FFRCT, 270 patients (82.6%) could potentially avoid ICA. Conclusion(s): CTCA optimized with nitroglycerin and beta-blockers is safe and effective for assessing CAD in select severe AS patients. Combining CTCA and FFRCT enhances diagnostic accuracy, potentially reducing the need for invasive angiography and streamlining TAVR workup. Categories: STRUCTURAL: Valvular Disease: Aortic.Copyright © 2024
Conference Name: Thirty-Sixth Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT)
Conference Start Date: 2024-10-27
Conference End Date: 2024-10-30
Conference Location: Walter E. Washington Convention Center, Washington, United States
DOI: https://dx.doi.org/10.1016/j.jacc.2024.09.992
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52702
Type: Conference Abstract
Subjects: aortic stenosis
computer assisted tomography
coronary angiography
coronary artery disease
hemodynamics
Appears in Collections:Conferences

Show full item record

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.